Reply: Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis
نویسندگان
چکیده
منابع مشابه
Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
UNLABELLED This retrospective study compared the effects of single and multiple administrations of (186)Re-hydroxyethylidenediphosphonate ((186)Re-HEDP) on palliation and survival of prostate cancer patients presenting with more than 5 skeletal metastases. METHODS A total of 60 patients were divided into 3 groups. Group A (n = 19) consisted of patients who had received a single injection; gro...
متن کاملLiver and lymph node metastases of prostate cancer visualized on post-therapy imaging after treatment with 188Re-HEDP.
A 76-year-old man with bone metastases of prostate cancer diagnosed a year ago was admitted for relief of bone pain (visual analogue scale: 90%) most markedly in cervical spine and upper extremities due to skeletal metastases. His serum prostate specific antigen level was markedly increased (351 ng/ml). After documentation of sufficient tracer uptake in multiple bone metastases on whole-body 99...
متن کاملEffectiveness and complications of 188Re-HEDP in palliative treatment of diffuse skeletal metastases
Introduction: Bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188Re-hydroxyethylidene diphosphonate (188Re-HEDP) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of ...
متن کاملCLODRONATE IN BONE METASTASES Clinical Urology CLODRONATE FOR TREATMENT OF BONE METASTASES IN HORMONE REFRACTORY PROSTATE CANCER
Introduction: Approximately 85% of patients who die from prostate cancer have bone metastases. Even though the radiological aspect of such metastases is osteoblastic, we currently know that these lesions are mixed, with coexisting blastic and lytic lesions, always beginning with bone lysis by osteoclast proliferation. Treatment options are palliative and have poor response, and when there is an...
متن کاملeffectiveness and complications of 188re-hedp in palliative treatment of diffuse skeletal metastases
introduction: bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188re-hydroxyethylidene diphosphonate (188re-hedp) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of 2.1 mev with a 15% γ-c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine
سال: 2012
ISSN: 0161-5505,2159-662X
DOI: 10.2967/jnumed.112.106294